Synergistic Integration of Positron Emission Tomography (PET) Imaging with AI, IoT, Blockchain, and Advanced Materials for Enhanced Bacterial Infection Diagnosis and Treatment

The inventive concept combines the original PET imaging agent composition with distinct technologies to create a more powerful system for diagnosing and treating bacterial infections, offering improved accuracy, efficiency, and personalized medicine.

The original patent disclosed a PET imaging agent composition for bacterial infection diagnosis, but it had limitations in image analysis, data security, and treatment monitoring. The new inventive concept addresses these limitations by integrating AI, IoT, blockchain, and advanced materials to provide a more comprehensive and effective solution.

The inventive concept comprises a PET imaging agent composition of 4-amino-2-[18F]-fluorobenzoic acid and 4-amino-2-[19F]-fluorobenzoic acid, combined with AI algorithms for image analysis and disease detection, IoT sensors for real-time treatment monitoring, blockchain technology for secure data storage and sharing, and novel materials for enhanced imaging sensitivity and specificity. This synergistic integration enables accurate diagnosis, personalized treatment, and efficient disease management.

The new claims introduce non-obvious combinations of the original PET imaging agent composition with AI, IoT, blockchain, and advanced materials, providing a novel and inventive solution for bacterial infection diagnosis and treatment.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT sensor configurations, blockchain architectures, or advanced materials. Variations could also include the integration of additional technologies, such as machine learning or robotics, to further enhance the system's capabilities.

The inventive concept has significant commercial potential in the healthcare industry, particularly in the areas of infectious disease diagnosis and treatment. Target markets include hospitals, research institutions, and pharmaceutical companies, with potential applications in personalized medicine, disease surveillance, and public health management.